Zygomycosis in Immunocompromised Non-Haematological Patients
Author Information
Author(s): Petrikkos George, Drogari-Apiranthitou Miranda
Primary Institution: National and Kapodistrian University of Athens, “ATTIKON” Hospital
Hypothesis
What are the clinical forms and risk factors associated with mucormycosis in immunocompromised non-haematological patients?
Conclusion
Mucormycosis can manifest in various clinical forms depending on the underlying condition, and prompt management is crucial to reduce mortality.
Supporting Evidence
- Mucormycosis is associated with high fatality rates, especially in immunocompromised patients.
- Diabetes mellitus is a significant risk factor, with 36-88% of cases occurring in diabetic patients.
- Prompt diagnosis and treatment can considerably reduce morbidity and mortality.
Takeaway
Mucormycosis is a serious fungal infection that can affect people with weakened immune systems, and recognizing its symptoms early can save lives.
Methodology
The review analyzes clinical presentations, risk factors, and treatment outcomes of mucormycosis in immunocompromised patients.
Limitations
Accurate estimation of incidence is challenging due to lack of global registry data and difficulties in collecting denominator data.
Participant Demographics
The study focuses on immunocompromised non-haematological patients, particularly those with diabetes, malignancies, and those undergoing solid organ transplantation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website